PURAPHARM (1498.HK)
- Previous Close
0.480 - Open
0.480 - Bid 0.470 x --
- Ask 0.480 x --
- Day's Range
0.460 - 0.480 - 52 Week Range
0.430 - 0.850 - Volume
270,500 - Avg. Volume
107,370 - Market Cap (intraday)
185.675M - Beta (5Y Monthly) 0.01
- PE Ratio (TTM)
-- - EPS (TTM)
-0.090 - Earnings Date Mar 31, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date May 31, 2017
- 1y Target Est
--
PuraPharm Corporation Limited, an investment holding company, engages in research, development, production, and sale of concentrated Chinese medicine granule (CCMG) and Chinese healthcare products in Hong Kong, Mainland China, and internationally. The company operates through five segments: China CCMG, Hong Kong CCMG, Chinese Healthcare Products, Clinics, and Plantation. It offers over the counter health products under the PuraGold, Oncozac, Haveron, and Immuzac brand names. The company also provides Chinese medicine clinic management system for general clinic management; and operates Chinese medicine clinics under the Nong's name that provide Chinese medicine services and CCMG products. In addition, it engages in the plantation and trading of raw Chinese herbs; manufacture and sale of traditional Chinese medicine decoction pieces; provision of modernized Chinese medicine services, Chinese medical diagnostic services; and research and development of bio-based polymeric materials. The company sells its products to hospitals, healthcare institutions, mobile clinics, and medicine practitioners, as well as operates an online platform. The company was incorporated in 1998 and is headquartered in Tai Po, Hong Kong.
www.purapharm.com479
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 1498.HK
View MorePerformance Overview: 1498.HK
Trailing total returns as of 6/16/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1498.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1498.HK
View MoreValuation Measures
Market Cap
189.63M
Enterprise Value
540.59M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.50
Price/Book (mrq)
1.71
Enterprise Value/Revenue
1.41
Enterprise Value/EBITDA
11.00
Financial Highlights
Profitability and Income Statement
Profit Margin
-9.27%
Return on Assets (ttm)
-1.51%
Return on Equity (ttm)
-26.80%
Revenue (ttm)
382.09M
Net Income Avi to Common (ttm)
-35.44M
Diluted EPS (ttm)
-0.090
Balance Sheet and Cash Flow
Total Cash (mrq)
36.9M
Total Debt/Equity (mrq)
327.13%
Levered Free Cash Flow (ttm)
65.88M